Author:
Wettstein Lukas,Conzelmann Carina,Müller Janis A.,Weil Tatjana,Groß Rüdiger,Hirschenberger Maximilian,Seidel Alina,Klute Susanne,Zech Fabian,Bozzo Caterina Prelli,Preising Nico,Fois Giorgio,Lochbaum Robin,Knaff Philip,Mailänder Volker,Ständker Ludger,Thal Dietmar Rudolf,Schumann Christian,Stenger Steffen,Kleger Alexander,Lochnit Günter,Sparrer Konstantin,Kirchhoff Frank,Frick Manfred,Münch Jan
Abstract
AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified α1-antitrypsin (α1-AT) as specific inhibitor of SARS-CoV-2. α1-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations. Our findings show that endogenous α1-AT restricts SARS-CoV-2 and repurposes α1-AT-based drugs for COVID-19 therapy.
Publisher
Cold Spring Harbor Laboratory
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献